Search results for "Acute hepatiti"
showing 4 items of 24 documents
Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis.
2014
<b><i>Objective:</i></b> To compare Masson's trichrome (MT), Sirius red (SR) and orcein staining in acute hepatitis (AH) and to correlate them with<b> </b>transient elastography (TE),<b> </b>a noninvasive method to assess hepatic fibrosis. <b><i>Methods:</i></b> We evaluated liver stiffness by TE in a cohort of 34 consecutive patients and assessed MT-, SR- and orcein-stained biopsies using the METAVIR scoring system and digital image analysis (DIA). <b><i>Results:</i></b> MT and SR both showed severe fibrosis (stage III-IV, DIA = 12.7%). Orcein showed absent or mild fibrosis (stage 0-II, DIA = 4.…
Therapy with lamivudine and steroids in a patient with acute hepatitis B and rapidly progressive glomerulonephritis.
2006
To the Editor: Tang et al.1 recently reported that lamivudine (LAM) improves renal outcome in patients with chronic hepatitis B virus (HBV) infection and membranous nephropathy. We would like to add our experience on acute hepatitis B and rapidly progressive glomerulonephritis.
Cardiorenal syndrome followed by acute hepatitis C in a patient with acute myeloid leukemia
1969
SUMMARY Cardiorenal syndrome involves altering cardiac and renal function. These patients frequently develop resistance to diuretic therapy, so that ultrafiltration should be applied in emergency for saving them. Concomitant presence of an active hematologic malignancy represents an important complicating factor. We present the case of an elderly patient with acute myeloid leukemia, appeared on the background of myelodysplastic syndrome who, during marrow aplasia occurred after the first course of induction chemotherapy, developed a cardiorenal syndrome, which required repeated sessions of hemodialysis. Complete hematologic remission and efficiency of fluid depletion therapy allowed the sec…
Acute hepatitis C: in search of the optimal approach to cure.
2006
Abstract IFN monotherapy for acute hepatitis C can be supported, but a strategy taking into account both baseline (clinical presentation, genotype, HIV coinfection) and early (spontaneous viral decay) virologic response should be developed from carefully conducted, controlled prospective studies comparing a “wait and see strategy”, and different schedules of PEG IFN monotherapy to optimize adherence and costs and to reduce the number needed to treat. The price of the ultimate success of therapy for AVH due to HCV, i.e. a stable and definitive clearance of HCV with no residual liver disease in the long term, should not be paid by a high number of patients who are treated needlessly.